The European Association for the Study of the Liver (EASL) has announced that ALIVER will be unveiled at The International Liver Congress™ in Amsterdam, The Netherlands.
The €7.8m project is funded by the EU Horizon 2020 research programme. Work started on ALIVER on 1 January 2017 and will end on 30 September 2020.
Each year over 170,000 people die from liver cirrhosis in Europe.
There are currently over 1,500 patients on the Eurotransplant waiting list for a new liver, and many more in other countries of the EU who are not members of the Eurotransplant network.
The ALIVER Consortium has developed a novel and innovative liver dialysis machine that aims to help the liver to naturally regenerate or, where that does not prove possible, to keep patients alive and healthy until a donated liver becomes available. DIALIVE has been demonstrated to be effective in pre-clinical tests.
DIALIVE removes dysfunctional albumin and endotoxins, infuses fresh, functional albumin and specifically targets systemic inflammation. Existing liver dialysis machines do not restore albumin function, have only a limited effect on systemic inflammation and do not improve survival rates.
The DIALIVE machine will be tested in clinical settings in the UK, Germany, France and Spain over the course of the project.
Two universities, four hospitals, two foundations and four industrial partners will work together to deliver DIALIVE.
Principal investigator for the project, Professor Rajiv Jalan, said, “We are delighted to be launching ALIVER here in Amsterdam with EASL. The project brings together scientific excellence in liver disease, clinical practice and industrial partnership, with EU funding.
“This is the future of medicine and health research and there is no better place to launch ALIVER than here at the EASL ILC.”